Physician profile
Aida Samson
NPI 1770853038
$12,689.61
in general payments reported to CMS, 2019-2025
39 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,335 · 2022: $2,836 · 2023: $2,829 · 2024: $3,332 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,394 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,393.72 |
| Education | $124.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,006.56 | 2021-2025 | |
| Janssen Biotech, INC. | $1,833.18 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,075.52 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,064.92 | 2021-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $720.54 | 2021-2024 | Sucraid, Sucraid |
| Pfizer INC. | $579.33 | 2021-2025 | |
| Celgene Corporation | $428.23 | 2021-2023 | Zeposia |
| Genzyme Corporation | $388.69 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $315.29 | 2021-2024 | Linzess |
| Aimmune Therapeutics, INC. | $303.89 | 2023-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $256.25 | 2021-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $235.02 | 2021-2023 | |
| Redhill Biopharma INC. | $228.50 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Ardelyx, INC. | $198.78 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $185.74 | 2024-2025 | Voquezna |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $168.64 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Braintree Laboratories, INC. | $151.94 | 2021-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $151.44 | 2022-2023 | Dupixent |
| Madrigal Pharmaceuticals | $146.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Olympus America INC. | $125.41 | 2021 | |
| Lilly USA, LLC | $123.97 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $115.98 | 2021-2024 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $107.90 | 2021-2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $101.79 | 2024-2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $76.17 | 2024 | Zymfentra, Vegzelma |
| Evoke Pharma, INC. | $69.34 | 2021 | |
| Mallinckrodt Hospital Products INC. | $67.99 | 2024 | Terlivaz |
| Amgen INC. | $67.66 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Pharmacosmos Therapeutics INC. | $66.75 | 2022-2024 | Monoferric |
| Palette Life Sciences, INC. | $58.57 | 2022 | |
| Vivus LLC | $52.52 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.07 | 2022-2024 | Zeposia |
| Ucb, INC. | $39.77 | 2021 | |
| Ferring Pharmaceuticals INC. | $33.27 | 2022-2023 | Rebyota |
| Novo Nordisk INC | $23.81 | 2025 | Wegovy |
| Gilead Sciences, INC. | $22.83 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.28 | 2023 | Andexxa |
| Boston Scientific Corporation | $19.75 | 2024 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $16.75 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Samson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.